Loading...
NPI 1639444904 · Little Rock, AR · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Daniel Kim is a ophthalmology physician provider located in Little Rock, Arkansas. This profile covers 13 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Daniel Kim |
| Address | 9601 Baptist Health Dr Ste 200 |
| City | Little Rock |
| State | AR |
| ZIP | 72205 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | March 20, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.1M |
| Medicaid | $18.2K |
This provider’s commercial scale is overwhelmingly Medicare‑driven: lifetime Medicare revenue is $2.1M compared with just $18.2K in Medicaid, so Medicare is the dominant payer for this clinician’s patient and revenue mix. Medicaid activity exists but is de minimis in absolute dollars and does not meaningfully move the provider’s overall revenue profile.
Medicare revenue is highly concentrated in intravitreal drug therapy: the top three Medicare codes account for 85.8% of total Medicare revenue, led by J0178, J2777, and 67028. That mix—aflibercept (J0178), newer anti-VEGF agent billing (J2777), and the intravitreal injection procedure (67028)—is consistent with a practice organized around frequent anti‑VEGF injections for retinal disease.
J0178 is by far the single largest Medicare revenue driver, reporting $1.4M and representing 67.2% of this provider’s Medicare revenue; nationally it ranks #521 of 3204 providers (84th percentile; typical, unremarkable volume for this code). The absolute dollar concentration in one drug code suggests operational focus on aflibercept administration, but the national rank indicates the provider’s J0178 volume is not unusually high relative to many peers.
Although injection codes dominate revenue, the provider also shows unusually high throughput on routine follow-up exams and retinal imaging: 92012 ranks #98 of 17177 providers (99th percentile; extreme outlier, far above typical national volume) and 92134 ranks #893 of 26868 providers (97th percentile; notably above typical national volume). These high percentiles for established‑patient intermediate exams and OCT imaging point to a high-volume follow‑up practice, consistent with frequent post‑injection monitoring.
On Medicaid the revenue mix mirrors Medicare in concentration: the top three Medicaid codes (67028, J0178, 92012) account for 87.5% of Medicaid revenue, with 67028 at $8K (43.8%) and J0178 at $6.1K (33.3%). Despite similar code concentration, the Medicaid dollar amounts are small in absolute terms, so Medicaid contributes little to the provider’s overall scale or cashflow compared with Medicare.
The provider’s competitive standing is mixed across codes: certain services show elevated relative activity (for example, J9035 ranks #79 of 1852 providers (96th percentile; typical, unremarkable volume) and 92134 is in the 97th percentile), while injection leadership by volume is not dominant nationally (J0178 at the 84th percentile is typical). For Medicaid, state ranks are constrained by small denominators—67028 is #7 of 17 in‑state (63th percentile) and J0178 is #4 of 4 in‑state (0th percentile)—so care should be taken interpreting those percentiles.
The provider reports several statistical outliers on Medicare service mix beyond injections: 99204 (new patient, moderate complexity) ranks #3894 of 227068 providers (98th percentile; extreme outlier, far above typical national volume), indicating above‑typical billing of moderate‑complexity new patient visits. Taken with the high 92012 and 92134 percentiles, this suggests both a high intake of new or complex referrals and a sustained high follow‑up throughput for retinal care.
The NPI tenure shows an established practice presence: the NPI was enumerated on 2012-03-20 (~14 years ago), indicating over a decade of billing history to assess operational patterns and payer mix stability. That tenure supports interpreting the observed code concentration and percentile patterns as persistent practice characteristics rather than short‑term anomalies.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,030 | $690 | $1.4M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 8,040 | $30 | $233.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,800 | $80 | $151.4K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 1,840 | $60 | $104.8K |
| J9035 | Injection, bevacizumab, 10 mg | 1,020 | $60 | $57K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,170 | $30 | $56.3K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 320 | $80 | $24.9K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 220 | $110 | $22.6K |
| J2778 | Injection, ranibizumab, 0.1 mg | 90 | $180 | $15.7K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 80 | $90 | $7.4K |
Showing 1–10 of 13
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
13 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 3 | 30 | 390 | $690 | $538.3K |
| J2777 | 13 | 20 | 12,180 | $30 | $504.5K |
| J2778 | 15 | 20 | 270 | $180 | $85K |
| 67028 | 3 | 40 | 270 | $80 | $51.1K |
| J9035 | 1 | 10 | 410 | $50 | $22.1K |
| 92014 | 95 | 370 | 150 | $70 | $19.1K |
| 92012 | 1 | 220 | 70 | $50 | $9.3K |
| 92235 | 6 | 10 | 80 | $90 | $6.9K |
| 92134 | 10 | 300 | 70 | $30 | $6K |
| 99204 | 47 | 2,100 | 40 | $100 | $5.4K |
Showing 1–10 of 13
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 400 | $20 | $8K |
| J0178 | Injection, aflibercept, 1 mg | 10 | $430 | $6.1K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 380 | $10 | $1.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 430 | $1 | $1.7K |
| J7999 | Compounded drug, not otherwise classified | 270 | $1 | $540 |
How this provider's Medicaid billing volume and revenue compare to other Arkansas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Arkansas median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 7 | 20 | 260 | $110 | $91.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 18 | 40 | 260 | $20 | $26.2K |
| J0178 | Injection, aflibercept, 1 mg | 4 | 10 | 120 | $180 | $20.7K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 24 | 100 | 120 | $30 | $14.3K |
| J7999 | Compounded drug, not otherwise classified | 4 | 10 | 150 | $1 | $420 |
Other providers in the same ZIP code as Daniel Kim, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.